The Vascular Injury drugs in development market research report provides comprehensive information on the therapeutics under development for Vascular Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Vascular Injury. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Vascular Injury and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Vascular Injury by nine companies/universities/institutes. The top development phase for Vascular Injury is preclinical with six drugs in that stage. The Vascular Injury pipeline has seven drugs in development by companies and two by universities/ institutes. Some of the companies in the Vascular Injury pipeline products market are: Chrysalis BioTherapeutics, Taipei Medical University and Harbin Medical University.
The key targets in the Vascular Injury pipeline products market include cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Decorin, and G1/S Specific Cyclin D1.
The key mechanisms of action in the Vascular Injury pipeline product include cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor with two drugs in Phase II. The Vascular Injury pipeline products include three routes of administration with the top ROA being Topical and four key molecule types in the Vascular Injury pipeline products market including Small Molecule, and Synthetic Peptide.
Vascular Injury overview
Vascular trauma refers to injury to a blood vessel—an artery, which carries blood to an extremity or an organ, or a vein, which returns blood to the heart. Vascular Surgeons categorize these injuries by the type of trauma that caused them: blunt or penetrating injury
For a complete picture of Vascular Injury’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
